STERIS plc (NYSE:STE) Shares Sold by ProShare Advisors LLC

Posted by on Apr 25th, 2023

ProShare Advisors LLC lowered its position in shares of STERIS plc (NYSE:STE – Get Rating) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,511 shares of the medical equipment provider’s stock after selling 129 shares during the quarter. ProShare Advisors LLC’s holdings in STERIS were worth $2,495,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in STERIS by 1.3% during the third quarter. Vanguard Group Inc. now owns 11,842,809 shares of the medical equipment provider’s stock worth $1,969,222,000 after acquiring an additional 146,928 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in STERIS by 10.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,087,287 shares of the medical equipment provider’s stock worth $845,914,000 after acquiring an additional 488,829 shares during the last quarter. State Street Corp boosted its position in STERIS by 1.1% during the third quarter. State Street Corp now owns 4,289,014 shares of the medical equipment provider’s stock worth $713,177,000 after acquiring an additional 48,229 shares during the last quarter. Invesco Ltd. boosted its position in STERIS by 89.8% during the first quarter. Invesco Ltd. now owns 953,983 shares of the medical equipment provider’s stock worth $230,645,000 after acquiring an additional 451,235 shares during the last quarter. Finally, London Co. of Virginia boosted its position in STERIS by 20.4% during the third quarter. London Co. of Virginia now owns 916,277 shares of the medical equipment provider’s stock worth $152,359,000 after acquiring an additional 154,959 shares during the last quarter. Institutional investors and hedge funds own 92.35% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $187.50 on Tuesday. The company’s fifty day simple moving average is $186.86 and its 200-day simple moving average is $185.56. STERIS plc has a 52 week low of $159.21 and a 52 week high of $238.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.48 and a quick ratio of 1.61.

STERIS (NYSE:STE – Get Rating) last issued its earnings results on Wednesday, February 8th. The medical equipment provider reported $2.02 EPS for the quarter, missing analysts’ consensus estimates of $2.19 by ($0.17). STERIS had a negative net margin of 0.58% and a positive return on equity of 12.86%. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the prior year, the business posted $2.12 EPS. The business’s revenue was up .8% on a year-over-year basis. On average, equities research analysts expect that STERIS plc will post 8.05 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 23rd. Stockholders of record on Friday, February 24th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date was Thursday, February 23rd. STERIS’s dividend payout ratio is presently -648.25%.

Analysts Set New Price Targets

A number of analysts recently issued reports on STE shares. JMP Securities decreased their target price on shares of STERIS from $250.00 to $240.00 and set a “market outperform” rating on the stock in a research report on Wednesday, February 15th. StockNews.com assumed coverage on shares of STERIS in a report on Thursday, March 16th. They issued a “buy” rating on the stock. Piper Sandler lowered shares of STERIS from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $215.00 to $197.00 in a report on Friday, April 14th. Stephens reiterated an “overweight” rating and issued a $220.00 price target on shares of STERIS in a report on Thursday, February 9th. Finally, TheStreet lowered shares of STERIS from a “b-” rating to a “c+” rating in a report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $220.80.

STERIS Profile

(Get Rating)

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites.

Read More

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Get Rating).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.